X4 Pharmaceuticals (XFOR) Capital Expenditures (QoQ) (2017 - 2024)
Powered by 
Analysis
X4 Pharmaceuticals (XFOR) Capital Expenditures (QoQ) (2017 - 2024) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn |
| 10 | X4 Pharmaceuticals | 510.43 Mn | 315.33 Mn | 7.19 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 5,732.20% |
| Mar 31, 2024 | 68.57% |
| Dec 31, 2023 | 337.50% |
| Sep 30, 2023 | 0.00% |
| Jun 30, 2023 | -11.11% |
| Mar 31, 2023 | -73.53% |
| Dec 31, 2022 | 277.78% |
| Sep 30, 2022 | -76.32% |
| Jun 30, 2022 | 72.73% |
| Mar 31, 2022 | 69.23% |
| Dec 31, 2021 | -35.00% |
| Sep 30, 2021 | -76.74% |
| Jun 30, 2021 | -82.66% |
| Mar 31, 2021 | 171.88% |
| Dec 31, 2020 | -146.37% |
| Sep 30, 2020 | 16,433.33% |
| Jun 30, 2020 | -98.38% |
| Mar 31, 2020 | 568.67% |
| Dec 31, 2019 | 2.47% |
| Sep 30, 2019 | 710.00% |